Deeply rooting in China and growing up to be a global leader, CARsgen commits to fulfill the unmet medical needs across the oceans, yet with a clear focus on the orphan indications in the western world but commonly occurred in China and Asia Pacific areas.
What is it you do and what is it that sets you apart as a company?
Deeply rooting in China and growing up to be a global leader, CARsgen commits to fulfill the unmet medical needs across the oceans, yet with a clear focus on the orphan indications in the western world but commonly occurred in China and Asia Pacific areas.
Can you comment on the market potential for your technology? Why do you believe this space so exciting?
CARsgen and its advanced technology in cell therapy areas hold great market potential and could be a nice candidate to remark today's supportive investment environment to global biotech start-ups. The most advanced technology, the shortest company history, and the quickest growth paces of CARsgen give me the confidence on the market potential for our company and technology.
What are the major milestones you've achieved to date and what is the next major milestone for the business?
Completed Phase I clinical trial of GPC3 CAR-T therapy in HCC, and bispecific EGFRvIII-EGFR CAR-T therapy in GBM. Submit IND and initiate Phase Ib trial of GPC3 CAR-T therapy in US and Phase II trial of GPC3 CAR-T therapy globally.
What is your key message to investors or prospective partners?
Invest into CARsgen and grasp the growth opportunity in both western and eastern markets.
What sort of investor are you looking to partner with to take the company through its next stage of development?
Investors who have supported similar biotech start-up and launched US IPO successfully; Investors who have more relevant resources in addition to the funding support.
Add Description Here
Biotech and Money is the influential community of senior life science decision makers
© 2016 All Rights Reserved By Biotech and Money
